Trial reportBlood2020
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Abstract readClinical Trial, Phase IClinical Trial, Phase IILetter
In one paragraph
Trial report in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Inclusion, characteristics, and reporting of older patients in recent registration trials for DLBCL.Blood advances · 2026Pooled it
- Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma.Journal of cancer research and clinical oncology · 2025Pooled it
- Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.Transplantation and cellular therapy · 2022Guideline
- Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.Blood advances · 2025Trial
- Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire.Nature communications · 2025Trial
- Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.Nature medicine · 2023Trial
- Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Quality of Life in CAR-T Cell Therapy.Hematology reports · 2026Review
- Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas.Blood neoplasia · 2026Article
- Research advances and application prospects of CAR-T therapy in the treatment of age-related diseases.Frontiers in immunology · 2026Review
- Predictors of response to CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a consolidated review.Current opinion in oncology · 2025Review
- Prophylactic Tocilizumab prior to infusion of CD19 CAR T-cells reduces therapy-related complications in older lymphoma patients.Annals of hematology · 2025Article
- Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis.Blood neoplasia · 2025Article
- JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma5. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS).International journal of hematology · 2025Article
- CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges.Journal for immunotherapy of cancer · 2025Review
- Role of Geriatric Assessment in Hematopoietic Stem Cell Transplant and Cellular Therapies.Current treatment options in oncology · 2025Review
- Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma.Bone marrow transplantation · 2025Article
- Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma.Nature reviews. Clinical oncology · 2025Review
- Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis.Blood advances · 2025Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Sattva S NeelapuDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Caron A JacobsonHematologic Oncology Treatment Center, Dana-Farber Cancer Institute, Boston, MA.
Olalekan O OluwoleDivision of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN.
Javier MunozDepartment of Lymphoma/Myeloma, Banner MD Anderson Cancer Center, Gilbert, AZ.
Abhinav DeolKarmanos Cancer Center, Department of Oncology, Wayne State University, Detroit, MI.
David B MiklosDivision of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA.
Nancy L BartlettDepartment of Medicine, Washington University School of Medicine, St. Louis, MO.
Ira BraunschweigMontefiore Medical Center, Department of Oncology, Albert Einstein College of Medicine, Bronx, NY.
Yizhou JiangKite, a Gilead Company, Santa Monica, CA; and.
Jenny J KimKite, a Gilead Company, Santa Monica, CA; and.
Lianqing ZhengKite, a Gilead Company, Santa Monica, CA; and.
John M RossiKite, a Gilead Company, Santa Monica, CA; and.
Frederick L LockeDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MWORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2MBreaking immune tolerance to Survivin in Multiple MyelomaK23CA201594 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI LOCKE, FREDERICK · 2015 to 2019
$821kNCI NIH HHS K23 CA201594NCI NIH HHS P30 CA013330NCI NIH HHS P30 CA016672
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAntigens, CD19Biological ProductsFemaleFollow-Up StudiesHumansImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisSurvival RateYoung AdultAntigens, CD19axicabtagene ciloleucelBiological Products
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.